The sodium glucose cotransporter-2 inhibitors are the newest diabetes drugs available. Have you got the basic concepts under your belt? Try these 6 questions and find out.
SGLT2 inhibitors haven’t been available for long, but EndocrinologyNetwork.com has covered the basics in our SGLT2 topic center. See how you fare on our 6-question Basic Training Quiz. Links at the end will take you to articles on the pros, the cons, and more on this new class of antidiabetes drugs.
1. Which of the following is NOT a primary advantage of treatment with SGLT2 inhibitors?
A. Neutral impact on hypoglycemia
B. Modest weight loss
C. Improved glycemia, A1c reductions (0.6% - 1%)
D. Insulin-independent action
E. Mild reduction in blood pressure
Answer: A. Neutral impact on hypoglycemia
2. SGLT2 inhibitors block the SGLT2 protein involved in what percentage of glucose reabsorption in the proximal renal tubule?
Answer: D. 90%
3. SGLT2 inhibitors are associated with a reduction in blood pressure of approximately:
A. 1% to 3%
B. 3% to 5%
C. 5% to 7%
D. 7% to 9%
Answer: B. 3% to 5%
4. As a result of their glucose-independent mechanism of action, SGLT2 inhibitors do not depend on level of Î²-cell function and are effective at all stages of disease.
Answer: A. True
5. The FDA requires manufacturers of SGLT2 inhibitors to conduct post-marketing studies and pharmacovigilance programs to learn more about:
A. Bladder cancer risk
B. Cardiovascular outcomes
C. Renal development (animal studies)
D. Pediatric safety/efficacy (bone health/development)
E. All of the above
F. A and B only
Answer: E. All of the above
6. In patients with an estimated glomerular filtration rate (eGFR) of between 45 and 60 mL/min/1.73m2, which of the following is FALSE:
A. There is no dosage adjustment required for the 3 FDA-approved SGLT2 inhibitors at the 2 dosage strengths available for each
B. Canagliflozin and empagliflozin may only be dosed at the lower of the 2 strengths for each (100 mg and 10 mg, respectively)
C. Dapagliflozin is not recommended in patients with an eGFR <60 mL/min/1.73m2
D. Empagliflozin not recommended in patients with an eGFR <60 mL/min/1.73m2
Answer: A. There is no dosage adjustment required for the 3 FDA-approved SGLT2 inhibitors at the 2 dosage strengths available for each
The following articles from the EndocrinologyNetwork SGLT2 Topic Center provide more detailed information on all of the quiz questions and answers:
Thank you for testing your SGLT2 knowledge. Please leave us a comment on the quiz, other material you would like to see included on EndocrinologyNetwork.com, or any thing else. -The Editors